CN101045152A - Traditional Chinese medicine composition for treating chronic pelvic inflammatory disease concomitant inflammatory swelling - Google Patents
Traditional Chinese medicine composition for treating chronic pelvic inflammatory disease concomitant inflammatory swelling Download PDFInfo
- Publication number
- CN101045152A CN101045152A CN 200610025301 CN200610025301A CN101045152A CN 101045152 A CN101045152 A CN 101045152A CN 200610025301 CN200610025301 CN 200610025301 CN 200610025301 A CN200610025301 A CN 200610025301A CN 101045152 A CN101045152 A CN 101045152A
- Authority
- CN
- China
- Prior art keywords
- rhizoma
- chinese medicine
- chronic pelvic
- inflammatory disease
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine for treating chronic pelvic inflammation with lumps is prepared from 6 Chinese-medicinal materials including burreed tuber, zedoary, flavescent sophora root, phellodendron bark, etc.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition of the women's of treatment chronic pelvic inflammatory disease concomitant inflammatory swelling, belong to field of medicaments.
Background technology
Chronic pelvic inflammatory disease is very multiple in married women, also betides unmarried women often.Clinically primary disease there is not basic Therapeutic Method.Doctor trained in Western medicine often use antibiotic for acute pelvic cavity therapeutic effect still can, but very undesirable for the chronic pelvic inflammatory disease effect.Doctor trained in Western medicine often adopts the treatment of the auxiliary chronic pelvic inflammatory disease of mode of physical therapy, but also has in-and-out problem.And the Chinese traditional treatment primary disease is from blood stasis-eliminating and stagnation-dissipating, and clearing away heat-damp and promoting diuresis is that method is started with, and often can obtain effect preferably.From modern pharmacology, the combination of these medicines has the blood flow of acceleration, improves blood circulation, promotes inflammation to absorb and dissipation, and can suppress the breeding of various bacteria and virus, thereby reaches the elimination pelvic inflammation, dwindles the effect of inflammation enclosed mass.
At present the bibliographical information about pelvic inflammatory disease has a lot, and the folk prescription treatment is arranged, and compound treatment is arranged, and external application combined treatment, the herbal drug enema in treatment in addition of adding for oral administration arranged.The report that also has some Chinese patent drugs for treatment chronic pelvics is as using FULE CHONGJI, anti-cervicitis sheet, danzhi xiaoyao pills etc.Also have the many pharmaceutical patent documents that can treat pelvic inflammatory disease, as the patent No. is 03124606.0, name is called the patent of scorching relaxation grain of woman and preparation method, disclose medicines such as Rhizoma Corydalis, Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Rhizoma Polygoni Cuspidati, RENKETENG, Caulis Sargentodoxae, Radix Glycyrrhizae, Folium Isatidis, Herba Taraxaci, Radix Et Rhizoma Rhei, Fructus Toosendan through being processed into granule, can treat pelvic inflammatory disease.
But, in the present various documents, the chronic pelvic inflammatory disease of treatment by Chinese herbs mostly be low weight, have only the performance of symptoms such as stomachache, leukorrhagia, and rare Chinese medicine at the abdominal part inflammatory mass.Because the struvite enclosed mass of abdominal part exists, and often causes very big influence to outpatients mental state, has also caused the touching of the course of disease.Many patients send out the author again repeatedly because of the inflammatory mass obstinate, the excision of finally having to adopt.Therefore, press for a kind ofly can effectively treat chronic pelvic inflammatory disease, especially with the medicine of inflammatory mass.
Summary of the invention
The purpose of this invention is to provide a kind of Chinese medicine composition for the treatment of chronic pelvic inflammatory disease concomitant inflammatory swelling, to remedy the blank spot of present treatment pelvic inflammatory disease with inflammatory mass.
Chinese medicine composition of the present invention meets the Chinese medical discrimination theory.Pelvic inflammatory disease belongs to the traditional Chinese medical science " lump in the abdomen " " dysmenorrhea " sick categories such as " leukorrheal diseases ", and it is considered to check yang-energy because heresy damp and hot or cold-damp is accumulated vessels of the uterus usually, causes qi depression to blood stasis, stagnation of QI and blood may bring about pain; Downward flow of dampness damages to appoint and is with two arteries and veins, so leukorrhagia; With the passing of time the stagnation of QI is wet stops, and hyperamization stasis of blood expectorant coagulates, so give birth to the lump in the abdomen enclosed mass.Chinese medicine composition of the present invention coagulates at qi depression to blood stasis expectorant just and establishes, and rhizoma sparganic, Rhizoma Curcumae promoting flow of QI and blood removing blood stasis with potent drugs are monarch drug, and Radix Sophorae Flavescentis, Cortex Phellodendri clearing away heat-damp and promoting diuresis are ministerial drug, the Rhizoma Cyperi circulation of qi promoting, and Radix Angelicae Sinensis is invigorated blood circulation and is adjuvant drug.We have obtained effect preferably in clinical use, alleviate and enclosed mass is reduced to effectively with stomachache, and effective percentage reaches more than 80%.
The consumption of drug component of the present invention, through summing up repeatedly clinically, the usage ratio scope that draws each medicine is:
Rhizoma sparganic 10-20%
Rhizoma Curcumae 10-20%
Radix Sophorae Flavescentis 10-20%
Cortex Phellodendri 10-20%
Rhizoma Cyperi 5-15%
Radix Angelicae Sinensis 15-30%
Chinese medicine composition preferred proportion of the present invention is:
Rhizoma sparganic 15-18%
Rhizoma Curcumae 15-18%
Radix Sophorae Flavescentis 15-18%
Cortex Phellodendri 15-18%
Rhizoma Cyperi 8-10%
Radix Angelicae Sinensis 20-30%
The best preferred proportion of Chinese medicine composition of the present invention is:
Rhizoma sparganic 18%
Rhizoma Curcumae 18%
Radix Sophorae Flavescentis 16%
Cortex Phellodendri 16%
Rhizoma Cyperi 9%
Radix Angelicae Sinensis 23%
The present invention is decocting directly, or alcohol extraction, or extracts volatile oil, adopts conventional method to make any oral preparations.But the active component that adopts medicine of the present invention is as raw material, add various conventional adjuvant required when preparing different dosage form, be prepared into any peroral dosage form commonly used as disintegrating agent, binding agent, filler etc. with the method for Chinese medicinal of routine, as tablet, granule, oral liquid, drop pill etc.
The preparation method of active component of the present invention is as follows:
Take by weighing medical material in proportion, place and have the extraction pot that extracts volatile oil, through conventional aqueous extraction-alcohol precipitation technology, obtain dry extract, be ground into fine powder, the volatile oil that will extract simultaneously is the carrier enclose with the beta-schardinger dextrin-again, with the fine powder mix homogeneously, promptly makes the active component of invention medicine after the clathrate drying.
The clinical research experiment
Go into the group data: among the 50 routine patients, the age is 12 examples below 30 years old, 30-40 year 25 examples, 41-50 year 13 examples.The course of disease is the shortest 6 months, and is the longest 20 years.
Clinical manifestation (1) lower abdominal pain or lumbosacral region are ached, or companion's profuse leukorrhea (2) gynecologial examination sees the uterus tenderness, and at least one side adnexa thickens, or and enclosed mass (3) ultrasound diagnosis have adnexa to increase thick or cyst.
Therapeutic Method: rhizoma sparganic 15-18g Rhizoma Curcumae 15-18g Radix Sophorae Flavescentis 15-18g
Cortex Phellodendri 15-18g Rhizoma Cyperi 8-10 Radix Angelicae Sinensis 20-30g
Be decocted in water for oral dose, every day secondary
Efficacy determination:--symptom and sign all normal (2) is----sx effectively, and adnexa thickens and alleviates (3) invalid----symptom and sign no change in (1) recovery from illness
Therapeutic outcome: 2 examples of fully recovering, effective 38 examples, invalid 10 examples.Total effective rate is 80%.
Zoopery: irritate stomach every day with active constituents of medicine 100 grams, the zoopery result that on Carrageenan causes rat paw edema shows that active constituents of medicine of the present invention can suppress to cause rat paw edema by carrageenin, P＜0.05.
The specific embodiment
Embodiment 1 (granule)
Take by weighing rhizoma sparganic 360g, Rhizoma Curcumae 360g, Radix Sophorae Flavescentis 320g, Cortex Phellodendri 320g, Rhizoma Cyperi 180g, Radix Angelicae Sinensis 460g, place and have the extraction pot that extracts volatile oil, through conventional aqueous extraction-alcohol precipitation technology, obtain dry extract, be ground into fine powder, the volatile oil that will extract simultaneously is the carrier enclose with beta-schardinger dextrin-80g again, with the fine powder mix homogeneously, promptly makes the active component 380g of invention medicine after the clathrate drying.The fine powder that will contain volatile oil clathrate compound is crossed 80 mesh sieves, makes granule with lactose 500g, protein sugar 50g, 90-95% ethanol 70g.
Embodiment 2 (sheet)
Take by weighing rhizoma sparganic 320g, Rhizoma Curcumae 320g, Radix Sophorae Flavescentis 300g, Cortex Phellodendri 300g, Rhizoma Cyperi 180g, Radix Angelicae Sinensis 560g, place and have the extraction pot that extracts volatile oil, through conventional aqueous extraction-alcohol precipitation technology, obtain dry extract, be ground into fine powder, the volatile oil that will extract simultaneously is the carrier enclose with beta-schardinger dextrin-96g again, with the fine powder mix homogeneously, promptly makes the active component 380g of invention medicine after the clathrate drying.The fine powder that will contain volatile oil is crossed 100 mesh sieves, makes granule with lactose 495g, protein sugar 45g, 90-95% ethanol 50g, tabletting behind the dried granule adding magnesium stearate 30g mixing.
Claims (4)
1. Chinese medicine composition for the treatment of women's chronic pelvic inflammatory disease concomitant inflammatory swelling is characterized in that said composition is made up of following medicine and deal: rhizoma sparganic 10-20%, Rhizoma Curcumae 10-20%, Radix Sophorae Flavescentis 10-20%, Cortex Phellodendri 10-20%, Rhizoma Cyperi 5-15%, Radix Angelicae Sinensis 15-30%.
2. a kind of according to claim 1 Chinese medicine composition for the treatment of women's chronic pelvic inflammatory disease concomitant inflammatory swelling, the preferable amount proportion of its compositions is: rhizoma sparganic 15-18%, Rhizoma Curcumae 15-18%, Radix Sophorae Flavescentis 15-18%, Cortex Phellodendri 15-18%, Rhizoma Cyperi 8-10%, Radix Angelicae Sinensis 20-30%.
3. as claimed in claim 1 or 2, a kind of best preferred proportion of Chinese medicine composition of the women's of treatment chronic pelvic inflammatory disease concomitant inflammatory swelling is: rhizoma sparganic 18%, Rhizoma Curcumae 18%, Radix Sophorae Flavescentis 16%, Cortex Phellodendri 16%, Rhizoma Cyperi 9%, Radix Angelicae Sinensis 23%.
4. as the Chinese medicine composition of claim 1,2 or 3 described treatment women chronic pelvic inflammatory disease concomitant inflammatory swellings, it is characterized in that and can make various oral formulations with following preparation method:
(1) takes by weighing the medicine of respectively distinguishing the flavor of according to the above ratio, place to have the extraction pot that extracts volatile oil,, obtain dry extract, and be ground into fine powder through conventional aqueous extraction-alcohol precipitation technology.
(2) will extract the volatile oil of gained, be the carrier enclose with the beta-schardinger dextrin-, and with above-mentioned fine powder mix homogeneously, crushing screening promptly gets the active component of medicine after the clathrate drying.
(3) in active constituents of medicine, add the needed conventional adjuvant of various dosage forms,, can be prepared into any peroral dosage form commonly used, as tablet, granule, oral liquid etc. according to formulation method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610025301 CN101045152A (en) | 2006-03-30 | 2006-03-30 | Traditional Chinese medicine composition for treating chronic pelvic inflammatory disease concomitant inflammatory swelling |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610025301 CN101045152A (en) | 2006-03-30 | 2006-03-30 | Traditional Chinese medicine composition for treating chronic pelvic inflammatory disease concomitant inflammatory swelling |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101045152A true CN101045152A (en) | 2007-10-03 |
Family
ID=38770255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610025301 Pending CN101045152A (en) | 2006-03-30 | 2006-03-30 | Traditional Chinese medicine composition for treating chronic pelvic inflammatory disease concomitant inflammatory swelling |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101045152A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101391065B (en) * | 2008-11-03 | 2011-04-13 | 刘文华 | Compound momordica seed pepper soup for treating urgent chronic pelvic inflammatory disease |
| CN102512563A (en) * | 2012-01-10 | 2012-06-27 | 周爱霞 | Medicament for treating chronic pelvic inflammatory disease |
| CN103040876A (en) * | 2012-12-17 | 2013-04-17 | 浙江佐力药业股份有限公司 | Preparation method for composition of solid traditional Chinese medicine particles |
| CN110339177A (en) * | 2019-08-20 | 2019-10-18 | 广西万寿堂药业有限公司 | Puerperal blood clot dispersing tablet and preparation method thereof |
| CN114366794A (en) * | 2022-01-17 | 2022-04-19 | 镇江市第一人民医院 | Preparation method and application of traditional Chinese medicine and traditional Chinese medicine oral liquid for treating pelvic inflammation |
-
2006
- 2006-03-30 CN CN 200610025301 patent/CN101045152A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101391065B (en) * | 2008-11-03 | 2011-04-13 | 刘文华 | Compound momordica seed pepper soup for treating urgent chronic pelvic inflammatory disease |
| CN102512563A (en) * | 2012-01-10 | 2012-06-27 | 周爱霞 | Medicament for treating chronic pelvic inflammatory disease |
| CN102512563B (en) * | 2012-01-10 | 2013-04-10 | 周爱霞 | Medicament for treating chronic pelvic inflammatory disease |
| CN103040876A (en) * | 2012-12-17 | 2013-04-17 | 浙江佐力药业股份有限公司 | Preparation method for composition of solid traditional Chinese medicine particles |
| CN103040876B (en) * | 2012-12-17 | 2015-03-25 | 浙江佐力药业股份有限公司 | Preparation method for composition of solid traditional Chinese medicine particles |
| CN110339177A (en) * | 2019-08-20 | 2019-10-18 | 广西万寿堂药业有限公司 | Puerperal blood clot dispersing tablet and preparation method thereof |
| CN114366794A (en) * | 2022-01-17 | 2022-04-19 | 镇江市第一人民医院 | Preparation method and application of traditional Chinese medicine and traditional Chinese medicine oral liquid for treating pelvic inflammation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1927330A (en) | Chinese medicine composition for treating gout and preparing method thereof | |
| CN103536761A (en) | Traditional Chinese medicine preparation for treating gout and preparation method of traditional Chinese medicine preparation | |
| CN103386022B (en) | Chinese medicine composition for treating tuberculous pleurisy | |
| CN1899342A (en) | Oral medicine for treating diabetes and its use | |
| CN101011544A (en) | Gout rapid recovery pill(capsule) and preparation technique thereof | |
| CN101045152A (en) | Traditional Chinese medicine composition for treating chronic pelvic inflammatory disease concomitant inflammatory swelling | |
| CN100444889C (en) | Chinese medicinal composition for treating mastopathy | |
| CN101537159B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN102727673A (en) | Chinese medicine composition for treating hysteromyoma and preparation method thereof | |
| CN100371012C (en) | Medicinal composition, and its preparing method and use | |
| CN102552520B (en) | Blood circulation-promoting and pain-stopping medicament and preparation process and application thereof | |
| CN101264314A (en) | Medicaments assembly for clearing heat and detoxication, activating blood circulation and removing stasis, and diminishing inflammation and reducing pain | |
| CN101380405B (en) | Traditional Chinese medicine preparation for treating cholelithiasis and preparation method thereof | |
| CN101332268A (en) | Medicine for treating rhinitis, sinusitis and preparation method thereof | |
| CN103157048B (en) | Traditional Chinese medicine composition for treating chronic pelvic inflammation and preparation method thereof | |
| CN101732469B (en) | Application of Chinese medicinal composition in preparation of medicament for treating aphonia | |
| CN104940423A (en) | Traditional Chinese medicine preparation for treating gout | |
| CN100367997C (en) | Medicine for treating arthrolithiasis and preparing method thereof | |
| CN104888137A (en) | Medicinal preparation for treatment of polycystic ovarian syndrome | |
| CN101194945A (en) | Tablet for treating headache and method for preparing the same | |
| CN1269518C (en) | Compound medicine for treating tuberculosis and its preparing method | |
| CN101732539B (en) | Medicament for treating gynecological diseases and preparation method thereof | |
| CN101264143B (en) | Chinese medicine preparation for treating gynecologic inflammation and preparation thereof | |
| CN101167915B (en) | Traditional Chinese medicine for treating chronic superficial gastritis and its preparation method | |
| CN101380414B (en) | Traditional Chinese medicine composition for treating gout and hyperuricemia and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20080425 Address after: Xinghu street Suzhou Industrial Park in Jiangsu province No. 218 nano Biotechnology Park A3 building room 313316 Applicant after: Suzhou Youseen New Drug R & D Co., Ltd. Address before: Jing Shanghai Road, Pudong New Area Zhangjiang hi tech Park No. 351 Applicant before: Shanghai Youseen New Medicine Exploitation Co., Ltd. |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |